Advances and Future of High-Grade Serous Ovarian Cancer Research
Time: Wednesday May 8, 2019
Place: Lecture hall 2, Biomedicum Helsinki 1, Haartmaninkatu 8, 00290 Helsinki
Link to the live webcast: https://vimeo.com/333732358
Ask for the password from hercules (at) helsinki.fi to follow the webcast.
| 09.00–09.55 | Registration and coffee | |
|
|
Session 1 |
|
| 09.55-10.00 | Sampsa Hautaniemi (HERCULES, Univ. of Helsinki) |
Welcome words |
| 10.00–11.00 | Keynote: Elizabeth M. Swisher (University of Washington) |
Clinical management of ovarian cancer |
| 11.00–11.20 | Sampsa Hautaniemi (HERCULES, Univ. of Helsinki) |
Computational approaches to tackle chemoresistance in high-grade serous ovarian cancer |
| 11.20–11.40 | Ulla Puistola (Univ. of Oulu) |
Biochemical studies on carsinogenesis and chemotherapy response in ovarian cancer |
| 11.40–12.00 | Sakari Hietanen (Univ. of Turku) |
Meeting an unmet need of treatment response prediction |
| 12.00-13.00 | Lunch (free for all participants) | |
| 12.00-13.00 | Scientific Satellite Symposium sponsored by AstraZeneca (closed meeting with invitation only)* | |
|
|
Session 2 |
|
| 13.00–14.00 | Keynote: Iain McNeish (Imperial College London) |
Decoding chaos: understanding the genome in ovarian high-grade serous carcinoma |
| 14.00–14.20 | Maarit Anttila (Univ. of Eastern Finland) |
Angiogenesis in ovarian cancer |
| 14.20–14.40 | Heini Lassus (Helsinki Univ. Hospital) |
Finding putative biomarkers to high-grade serous ovarian cancer using tissue microarray |
| 14.40–15.00 | Kalle Savolainen (Tampere Univ. Hospital) |
Ovarian cancer research in Tampere Univ. Hospital Cancer Centre |
| 15.00–15.30 | Coffee break | |
|
|
Session 3 |
|
| 15.30–15.50 | Liisa Kauppi (CHEMORESPONSE, Univ. of Helsinki) |
DNA repair mechanisms in HGSOC: the molecular biology view |
| 15.50–16.05 | Wojciech Senkowski (University of Copenhagen) |
Poster presentation: Establishment of optimal in vitro conditions for culture of ovarian cancer organoids |
| 16.05–16.20 | Anniina Färkkilä (Dana-Farber Cancer Institute & Harvard Medical School) |
Poster presentation: Immunogenomic determinants of response to combination of niraparib and pembrolizumab in recurrent, platinum-resistant ovarian cancer |
| 16.20–16.30 | Kirsti Siitonen | Views and experiences of an HGSOC patient |
Poster session |
||
| 16.30-18.00 | Poster session and Sponsors' exhibition | |
Dinner |
||
| 19.00- | Dinner at restaurant Töölönranta |
* The Scientific Satellite Symposium is an official part of “Advances and Future of High Grade Serous Ovarian Cancer Research” symposium program organized by University of Helsinki and HERCULES research project. AstraZeneca sponsors Scientific Satellite Symposium and participation is allowed by invitation only.